Publications by authors named "Nabil Andrawis"

Claim this Profile
A
Aprocitentan for Blood Pressure Reduction in Black Patients.
John M Flack, Markus P Schlaich, Michael A Weber, Mouna Sassi-Sayadi, Krzysztof Narkiewicz, Nabil S Andrawis

Hypertension· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Deepak L Bhatt, Harold E Bays, Michael Miller, James E Cain, Katarzyna Wasilewska, Nabil S Andrawis

Nat Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Aditi R Saxena, Juan P Frias, Donal N Gorman, Rene N Lopez, Nabil Andrawis

Diabetes Obes Metab· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Deepak L Bhatt, Harold E Bays, Michael Miller, James E Cain, Katarzyna Wasilewska, Nabil S Andrawis

Nat Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US.
Eric M Ammann, Ellen S O'Brien, Dejan Milentijevic, Akshay A Kharat, Darren A Talbot, Nabil S Andrawis

Heliyon· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis